Using a series of classical protein purification techniques, coupled with more modern molecular approaches, a family of neuropeptides, the Phoenixins, was identified to be produced in brain and heart, and to bind selectively in pituitary gland, ovary and brain. These same binding sites were revealed, using a novel receptor identification strategy, to express the orphan G protein-coupled receptor, GPR173, the expression of which was required for the actions of phoenixin both in vivo and in vitro. In fact, studies using small interfering RNA molecules to compromise GPR173 expression revealed the physiologic relevance of the initially reported pharmacologic actions of the peptides. Those include not only the reproductive actions of the peptides in brain and pituitary gland, but also a CNS site of action in the maintenance of fluid and electrolyte homeostasis. Additional pharmacologic actions of the phoenixins have been described and the race is on to establish the physiologic relevance of those actions as well as the therapeutic potential of phoenixin analogs.
Discovery of the phoenixin peptides
Using a bioinformatics approach, our collaborator, Aaron Hsueh at Stanford University, screened the human genome and identified multiple sequences predicted to encode previously unrecognized, secreted peptides [21] . One of these sequences, eventually identified to encode the protein sequence of the pre-pro-hormone for phoenixin, was conserved across species, leading Dr. Hsueh to hypothesize that this evolutionary conservation promised physiologic relevance in mammals. We joined then with the Stanford lab and our collaborators at Phoenix Pharmaceuticals (Burlingame, CA) to produce the predicted peptide sequence, raise antibodies, and identify sites of peptide production. Those antibodies also were employed to immuno-precipitate the endogenous peptide for purification and validation of the predicted sequence. Because of the presence of multiple dibasic cleavage sites in the prohormone, we hypothesized that numerous isoforms of the final postranslationally modified product would be found. Indeed, two major isoforms of phoenixin were identified to be produced by posttranslational processing, a 20 amino acid, C-terminally amidated peptide (predominantly produced in brain) and an N-terminally truncated, 14 amino acid form in heart (Fig. 1 ). To date, at least in our hands the 20 and the 14 amino acid forms have similar biological actions.
Radioimmunoassays were developed to quantify peptide content in tissue extracts and plasma and, in the initial stages of peptide purification, to gauge recoveries from large tissue extracts. In addition more recent immunohistochemical analyses have revealed the presence of phoenixin-like immunoreactivity (PNX-li) in sites other than those described in the original discovery paper [21] , where cells positive for phoenixin staining were described in hypothalamic and brain stem structures (Table 1) . Indeed, PNX-li has been identified in the dorsal root, nodose and trigeminal ganglia [7] , the amygdala, spinothalamic and spinocerebellar tracts, and in the crypts of the small bowel [9] . Antibodies we employ recognize both the 14 and the 20 amino acid form of phoenixin and as with the bioactive peptides, we do not discriminate between the two. The prominent localization of PNX-li in hypothalamic sites important in reproduction and fluid and electrolyte homeostasis, as well as specific phoenixin binding in the hypothalamus led us to examine the hypothalamus as a possible site of action of the peptide. While we initially hypothesized reproductive actions of phoenixin; however, the presence of immunoreactivity in the paraventricular (PVN) and supraoptic nuclei (SON) led us and others to hypothesize additional pharmacologic actions of the peptides in brain.
Pharmacologic effects of the phoenixin peptides

Reproduction
Although we could not distinguish the exact localization of PNX-li in the median eminence (internal versus external laminae), the presence of the peptide close to the fenestrated capillary endothelial cells suggested its potential delivery to the anterior lobe of the pituitary gland. We initially failed to observe any significant effects of a wide range of phoenixin concentrations on hormone release from dispersed anterior pituitary cells harvested from male or female rats; however, when coincubated with gonadotropin releasing hormone (GnRH) both phoenixin-20 and phoenixin-14 potentiated the action of the releasing factor to stimulate luteinizing hormone (LH) release and as well increased gonadotropin mRNA levels [21] . This was observed only in cells harvested from random cycle female, not male rats. Furthermore, we demonstrated that phoenixin-20 acted by itself to increase GnRH receptor mRNA levels in these cultures, and potentiated GnRH-induced up regulation of the message as well. Thus, in addition to an acute effect on the secretory event, phoenixin appeared to regulate cellular responsiveness and hormone production. Not only did phoenixin activate reproductive hormone secretion by an anterior pituitary site of action [21] , it also when injected i.c.v. increased, in a dose-related fashion, plasma LH levels in conscious, unrestrained, diestrous, female rats [15] , an action that was absent when the receptor for the peptide was compromised uniquely in the hypothalamus and not the pituitary gland (vida infra). Therefore, the peptide appeared to act at two levels of the hypothalamo-pituitary-gonadal (HPG) axis (Fig. 2) . Another group demonstrated an action of phoenixin-20 to stimulate GnRH mRNA levels in and peptide release from immortalized hypothalamic neurons in vitro [17] , supporting our two-site hypothesis.
Ingestive behavior
The presence of PNX-li in brain sites associated with ingestive behaviors [9, 21] suggested to Stengel and colleagues [14] that the peptide (s) might alter food intake. Indeed, when administered centrally but not peripherally, phoenixin-14 altered food intake in ad libitum fed, male rats in a time of day selective manner. When injected during the light phase, during a time in which the animals normally do not consume significant amounts of their total daily intake, the peptide stimulated feeding. However, the phoenixin-injected animals compensated during the dark phase by consuming less food such that their twenty-four hour intakes did not differ from those in control animals, suggesting that phoenixin-14 shifted the daily rhythm of ingestion in the treated animals. The authors reported a trend toward increased locomotor activity in the treated rats that did not reach statistical significance; however, they suggested this potential arousal effect should be studied further [14] . Similarly, the increased drinking behavior observed in the treated animals did not attain statistical significance and, as the authors appropriately suggested [14] this should be re-examined under conditions where food is not available, an approach that revealed for us the unique effect of obestatin on water, not food intake [11, 12] .
Neurohypophyseal hormone secretion
PNX-li has been demonstrated in the PVN and SON nuclei of the hypothalamus [1, 4] . When hypothalamic slice preparations were exposed to phoenixin-20 in vitro, magnocellular PVN neurons were observed to depolarize and display increased action potential discharges [3] . When incubated with isolated hypothalamic explants, phoenixin-20 stimulated selectively vasopressin (AVP) but not oxytocin (OT) release suggesting an effect on vasopressinergic, but not oxytocinergic neurons within the PVN. These in vitro observations were extended to live animal protocols. Lateral cerebroventricle administration of phoenixin-20 increased plasma AVP, but not OT levels in conscious male and random cycle female rats in a time-and dose-related fashion [3] . Additionally, central administration of pheonixin-20 activated early gene expression (cFOS staining) in the SON of male rats.
Other central nervous system actions of the phoenixins
The observation that phoenixin-20 increased GnRH receptor mRNA levels [21] led Jiang and colleagues [5] to examine the potential actions of the peptide on anxiolytic behaviors in mice. Using open-field and plus maze approaches, they demonstrated that phoenixin-14 exerted anxiolytic effects when injected into the anterior hypothalamic area but not the central amygdala. A potent GnRH antagonist blocked the action of phoenixin-14, not only with regard to the induction of anxiolytic behavior, but also the ability of the peptide to lower core body temperature. The same group [6] employed mice to determine if the peptide altered memory processing and demonstrated a significant stimulatory effect when administered i.c.v. at one dose on memory formation and retention. As in their other behavioral model [5] the action of phoenixin-14 could be blocked by the GnRH antagonist [6] . This suggested that kisspeptin producing neurons which control GnRH neuron activity or alternatively GnRH neurons directly may be a downstream targets of phoenixin not only in terms of the neuroendocrine roles played by GnRH, but other behavioral actions as well. GnRH, in addition to its pituitary site of action to stimulate gonadotropin secretion, acts in brain to stimulate reproductive behaviors [8] . Therefore, it will be interesting to determine in future studies if phoenixin interacts with GnRH in the activation of lordosis behavior An additional nervous system action of the phoenixins was identified by Cowan and colleagues [1] . PNX-li was identified in dorsal root ganglion cells and terminals in the superficial layers of the dorsal horn. Retrograde tracing identified phoenixin positive cells in the ganglion that appeared to project to the dorsal horn of the spinal cord [7] . Intrathecal administration of phoenixin-14 amide interrupted visceral but not pain responses in mice [7] . Administration of phoenixin-14 subcutaneously into the nape of the neck of mice resulted in intense scratching behavior that could be blocked by pretreatment with a kappa opioid agonist. These authors hypothesized that phoenixin acted as pruritogen in this species [1] .
Peripheral actions of the phoenixins
In addition to the actions of the peptides in the anterior lobe of the pituitary gland [15, 21] , the only other description to date of an action of phoenixin outside of the nervous system is in an ischemia/reperfusion model in isolated rat hearts [10] . Those investigators demonstrated that phoenixin-14 exerted cardioprotective effects that included reduced infarct size and improved recovery following ischemia. They suggested that these protective actions may have been due to an action of the peptide to activate ERK1/2, Akt and eNOS phosphorylations. Interestingly, these same authors reported that plasma phoenixin levels as determined by a commercially available ELISA rose significantly following a meal in animals fed a standard meal, but not those maintained on a high fat diet [10] . They speculated that phoenixin, of hypothalamic origin, may cross the blood brain barrier to exert actions in the periphery.
Physiologic effects of the phoenixin peptides
In the absence of a suitable antagonist, or genetically altered animals, the options available for the establishment of the physiologic relevance of the pharmacologic actions of the phoenixins have been limited, but not unavailable. The initial manuscript describing the discovery of the phoenixins, utilized small interfering RNA (siRNA) molecules targeting phoenixin to demonstrate that compromise of hypothalamic peptide content interrupted the normal rat estrous cycle and reduced GnRH mRNA levels in the anterior pituitary gland [21] . Those studies did not identify the importance of the hypothalamic, versus the pituitary actions of the peptide in the regulation of reproductive hormone secretion, but suggested a two-site model. This led our group to the search for the identity of a cognate, phoenixin receptor. It was hypothesized that once such a receptor was identified, the actions of phoenixin in one versus the other site could be established. Less than three years later the original phoenixin discovery team successfully identified an orphan G protein-coupled receptor that would reveal not only the physiologic relevance of the reproductive effects of phoenixin but also its dual sites of action [15] .
The search for the phoenixin receptor
Using a deductive reasoning strategy patented by one of the peptide's discovery team members [18] , the previously orphaned G protein-coupled receptor GPR173 was identified to be a candidate phoenixin receptor [15] . Our group implemented this same strategy to successfully "de-orphanize" the cognate receptors for neuronostatin [2] (another peptide hormone discovered through the collaborative efforts of Dr. Aaron Hsueh) [13] , the pancreatic hormone, connecting-(also known as C-) peptide [20] , and adropin [16] .
In the original discovery paper [21] , phoenixin was observed to increase cAMP accumulation in a rat pituitary adenoma cell line suggesting an interaction with a G protein-coupled receptor. Cells responsive to phoenixin were screened for the expression of orphan G protein-coupled receptors, identified by homology cloning, and candidate receptors were identified that were commonly expressed in those cell lines. The only candidate observed to be expressed where specific binding for phoenixin had been identified [21] was GPR173. siRNAs were designed and validated to significantly reduce GPR173 mRNA levels in vivo and in vitro [15] . The resulting "knockdown" prevented the ability of phoenixin to potentiate the action of GnRH on LH release in vitro and interrupted the rat estrous cycle when administered in vivo [15] . These results supported the hypothesis that phoenixin acted at two sites, hypothalamus and pituitary gland, to contribute to the regulation of reproductive hormone secretion. While the mechanisms underlying those sites of action of phoenixin remain to be comprehensively examined, the information concerning the identification of GPR173 as a potential phoenixin receptor was shared in prepublication with collaborators in Toronto, who went on to support our hypothesis of the importance of the interaction of phoenixin and GPR173 in GnRH production and release in transformed cell lines in vitro and to suggest potential downstream signaling cascades activated by that interaction [17] . Current work in our laboratory seeks to establish the physical interaction of phoenixin peptides with Gpr173 and identify the G proteins activated by that interaction.
in situ hybridization histochemistry identified multiple central nervous system sites where GPR173 was expressed [15] . The identification of signal in PVN and SON, sites previously identified to contain PNX-li led to the discovery that the peptide stimulated AVP release, a finding that was extended to indicate the possibility that a second hypothalamic action of phoenixin might be physiologically relevant [3] . Future studies will be needed to establish whether or not GPR173 "knockdown" alters AVP release to physiologically relevant stimuli (e.g. hyperosmolarity or hypovolemia). Similar approaches may facilitate the examination of the physiologic relevance of many other to date identified CNS actions of the peptides [1, 5, 6] , because of the broad expression pattern of the receptor [15] .
Do the phoenixins exert physiologically relevant actions in humans?
Information from human studies is scarce; however, one group has demonstrated a correlation between plasma phoenixin-14 and both LH and androgen levels in women with polycystic ovary syndrome [19] , suggesting that the reproductive effects observed in rodents [15, 21] may model human reproductive physiology or pathophysiology. The anxiolytic actions of phoenixin in mice [5] may have a correlate in the observation of a negative association of plasma phoenixin levels with anxiety scores in obese men [4] . Finally the actions of phoenixin on memory formation and retrieval [6] may have predicted the observation of a positive association of plasma phoenixin levels with memory function in aged humans with cognitive complaints [22] .
Conclusions
Although only recently identified, the phoenixins have been demonstrated to be produced in a limited number of tissues, but to have diverse biologic actions, some of which may be physiologically relevant, thus providing the framework for the potential development of novel therapeutic tools. Much more information is needed however and multiple questions remain. Is GPR173 the only receptor to recognize the peptides? What membrane proteins associate with or are influenced by activation of the receptor and what are the tissue specific signaling cascades underlying the pharmacologic and physiologic effects of the peptides? Are there single nucleotide polymorphisms of either peptide or receptor expression in the human population that reveal the importance of this ligand/receptor pairing? Will modern molecular tools for the activation or inactivation of this interaction support the hypothesized role for the peptides in reproduction and the regulation of fluid and electrolyte homeostasis? Can the reported actions in Langendorf heart preparations be translated into novel approaches for improvement of cardiac function following ischemic events? Are the gonads targets of circulating phoenixin? Tools are now available to answer these and many other questions. What is needed, to state the obvious, are the financial resources to pursue those questions.
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